The American Parkinson Disease Association (APDA) is urging U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. to move forward with implementation of the National Parkinson’s Project. The project is an integrated national plan to prevent, diagnose, treat, and ultimately cure Parkinson’s disease.
News
Herantis Pharma has reported new Phase 1b biomarker data that support the expected mechanism of action of HER-096, its potential disease-modifying treatment for Parkinson’s disease. The Phase 1b trial (NCT06659562) evaluated the safety of HER-096 and explored early signs of biological activity in both healthy volunteers and…
GT-02287, an oral therapy being developed by Gain Therapeutics, was associated with improvements in motor function over three months in people with Parkinson’s disease, including participants both with and without GBA1 mutations. The findings come from an open-label Phase 1b trial (NCT06732180), which also showed lower levels…
Neuralight said a newly completed study showed its machine learning-based system monitoring eye movements via webcam is more sensitive than traditional tests used for tracking Parkinson’s disease progression. “For the first time, a biomarker has outperformed the neurological gold standard in tracking Parkinson’s disease over time, unlocking a new…
Two proteins found on the surface of dopaminergic neurons, the nerve cells that are lost in Parkinson’s disease, may play a crucial role in the spread of toxic alpha-synuclein clumps throughout the brain, and blocking them could slow or halt disease progression. That’s according to a study from Yale…
A new high-tech imaging tool that can “see” the toxic protein clumps thought responsible for Parkinson’s disease is heading into clinical trials to help determine if an experimental therapy can slow the disease. Synusight Biotech has licensed its specialized positron emission tomography (PET) tracer ¹⁸F-FD4 to Abli Therapeutics…
A new collaboration aims to accelerate the development of large-molecule therapeutics capable of entering the brain to treat neurological conditions, starting with Parkinson’s disease and Alzheimer’s disease. The effort, from Mercury Bio and Meta-Flux, will combine Mercury’s yeast extracellular vesicle (yEV) technology, designed to deliver therapeutic molecules into…
A new study will investigate the long-term safety and effects of the experimental treatment buntanetap in people with Parkinson’s disease, according to Annovis Bio, the therapy’s developer. The open-label extension (OLE) study (NCT07284784) is expected to enroll about 500 adults with Parkinson’s disease, ages 40 to 85,…
Zambon Biotech has dosed the first patient in its clinical trial testing Crexont (IPX203) — an extended-release formulation of carbidopa/levodopa (CD/LD) that aims to ease so-called off episodes — among people with advanced Parkinson’s disease. With several locations now open in Italy, Poland, and Spain, the Phase…
Throughout 2025, the team at Parkinson’s News Today has reported on the latest research updates and advances in care related to Parkinson’s disease. Below is a list of the top 10 most-read articles we published this year. We look forward to continuing to serve as a source of news…
Recent Posts
- Guest Voice: What de facto parenting can teach us about Parkinson’s
- Parkinson’s advocates urge implementation of new federal plan
- New trial data show early biological signals for Parkinson’s therapy
- Taking time for self-care is crucial as a caregiver
- Early trial data suggest GT-02287 may ease Parkinson’s symptoms